The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: A meta-analysis

Abstract

Bone metastasis leads to skeletal-related events in final-stage cancer patients. The incidence of prostate and lung cancers increases yearly; these cancers readily invade the bone. Some recent studies have found that serum osteoprotegerin (OPG) levels may be altered in patients with bone metastasis, whereas other reports have produced inconsistent findings. Hence, we conducted a meta-analysis to examine the effects of lung and prostate cancer on serum OPG levels. A systematic literature search was conducted using PubMed, Medline, and CNKI to identify relevant studies. A total of 11 studies were included. The standardized mean difference (SMD) and 95% confidence interval (95% CI) of the bone metastasis (BM) group, the non-bone metastasis (BM-) group and healthy controls were calculated. In prostate cancer, serum OPG levels in the BM group were higher than in the BM-group and healthy controls. Additionally, no significant difference in serum OPG levels was found between the BM-group and healthy controls. In lung cancer, serum OPG levels in the BM and BM-groups were significantly increased compared with healthy controls. However, no significant difference in serum OPG levels was found between the BM and BM-groups. Studies with larger sample sizes are required to confirm these findings.